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Background and Aims: Diabetes has a significant, negative impact on the quality of life 
(QoL) of patients, thus, the protection and improvement of QoL is an important goal of 
diabetes care. The Audit of Diabetes-dependent Quality of Life (ADDQoL) is a questionnaire 
that measures present QoL and average weighted impact (AWI) of diabetes on QoL across 
18 individual life domains, including work, social life and enjoyment of food. One of the 
objectives of this study was to show, using the ADDQoL, that the perceived negative impact 
of diabetes on QoL is reduced in patients on a combination of insulin glargine (LANTUS®) + 
insulin lispro (Humalog®), as compared with NPH insulin + regular human insulin. 
Materials and Methods: This was a 32-week, multicenter, open-label, randomized 
crossover clinical trial comparing once-daily insulin glargine + insulin lispro with once- or 
twice-daily NPH insulin + regular human insulin, in patients with Type 1 diabetes. Patients 
(n=48; 62.5% female; mean age 42 ± 11.4 years) were randomized to receive either 
Treatment Sequence A (insulin glargine + lispro followed by NPH insulin + regular human 
insulin; n=22) or Treatment Sequence B (NPH insulin + regular human insulin followed by 
insulin glargine + lispro; n=26). The ADDQoL was used initially, and after each treatment 
period. In addition, treatment satisfaction was assessed using the Diabetes Treatment 
Satisfaction Questionnaire (DTSQ). 
Results: For all patients combined, the mean present QoL baseline score was 1.3, reflecting 
‘good’ (rather than ‘very good’ or ‘excellent’) present QoL. Present QoL improved 
significantly with insulin glargine + lispro but did not change with NPH insulin + regular 
human insulin (p=0.014; 95% confidence interval [CI]: 0.07; 0.55; Table). The mean AWI 
score was -1.8 initially, indicating a mean negative impact (actual range -6 to +3) of diabetes 
on QoL. After the total treatment period, the mean AWI score improved by 0.4 with insulin 
glargine + lispro and by 0.1 after NPH insulin + regular human insulin, indicating a beneficial 
effect of insulin glargine + lispro (p=0.033). Moreover, treatment satisfaction for the total 
treatment period was markedly improved after treatment with insulin glargine + lispro 
compared with NPH insulin + regular human insulin (mean: 32.2 ± 3.4 vs 23.9 ± 7.2; 
p<0.0001). 
Conclusion: This study shows that insulin glargine + lispro improves treatment satisfaction, 
reduces the negative impact of diabetes on QoL, and improves QoL per se.  
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ADDQoL 
scores 
(mean ± 
SD) 
Present QoL Average weighted impact score 
 
Sequence A: 
insulin glargine + 
lispro/NPH 
insulin + regular 
Sequence B: 
NPH insulin + 
regular/ insulin 
glargine + lispro 
Sequence A: 
insulin glargine + 
lispro/NPH 
insulin + regular 
Sequence B: 
NPH insulin + 
regular/ insulin 
glargine + lispro 
Baseline 1.4 ± 0.8 1.2 ± 1.3 -1.6 ± 1.2 -1.9 ± 1.3 
End of 
treatment 
period 1 
1.6 ± 0.8 1.2 ± 1.2 -1.2 ± 0.6 -1.8 ± 1.2 
End of 
treatment 
period 2 
1.3 ± 0.8 1.6 ± 0.9 -1.5 ± 1.2 -1.6 ± 1.2 
 Insulin glargine + lispro 
NPH insulin + 
regular 
Insulin glargine + 
lispro 
NPH insulin + 
regular 
Total 
treatment 
period 
1.6 ± 0.8* 1.3 ± 1.0 -1.4 ± 0.9† -1.7 ± 1.2 
 
*p=0.014 vs NPH insulin + regular; †p=0.033 vs NPH insulin + regular  
 
Keyword (Complete):  29 Insulin therapy  
 
